Fibrotic signaling pathway

The fibrotic signaling pathway represents a complex network of molecular interactions, primarily driven by transforming growth factor-beta (TGF-beta), that regulates the pathological accumulation of extracellular matrix (ECM) components in tissues. Central to this process is the activation of myofibroblasts, which differentiate from resident fibroblasts or other cell types in response to chronic injury and pro-fibrotic stimuli such as PDGF, CTGF, and Wnt ligands. Downstream signaling typically involves canonical SMAD-dependent pathways and non-canonical cascades like MAPK, PI3K/Akt, and Rho GTPases, which collectively promote the transcription of collagen, fibronectin, and other structural proteins. While essential for normal wound healing, persistent activation of these pathways leads to organ scarring, architectural distortion, and eventual failure in diseases such as idiopathic pulmonary fibrosis and liver cirrhosis. Therapeutic strategies currently focus on multi-kinase inhibitors like Nintedanib and cytokine modulators like Pirfenidone, though achieving high selectivity remains a significant challenge due to the vital role these pathways play in immune homeostasis and tissue repair.

Other names

Fibrogenesis pathwayPro-fibrotic signaling cascadeMyofibroblast activation pathwayExtracellular matrix remodeling pathway

Inhibition of TGF-beta signaling, blockade of connective tissue growth factor (CTGF), tyrosine kinase inhibition (VEGFR/FGFR/PDGFR), antagonism of lysophosphatidic acid receptor 1 (LPAR1), and modulation of the Rho/ROCK pathway to prevent myofibroblast activation and collagen deposition.